A carregar...
Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
Pembrolizumab is a full-length human immunoglobulin G4 (IgG4) monoclonal antibody directed against the immune checkpoint PD-1 to remove its binding with PD-L1 and thus to restore an anti-tumor immune response of T cells. Pembrolizumab is one of the most advanced immune checkpoint inhibitors for canc...
Na minha lista:
| Publicado no: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6527794/ https://ncbi.nlm.nih.gov/pubmed/31190995 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S151023 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|